Akebia Therapeutics Inc. (NASDAQ:AKBA) traded with a subtraction of -$0.01 to $0.34 on Thursday, a downside of -3.93 percent. An average of 1,258,936 shares of common stock have been traded in the last five days. There was a fall of -$0.0299 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 1,790,799 shares traded, while the 50-day average volume stands at 2,985,610.
AKBA stock has decreased by -4.32% in the last month. The company shares reached their 1-month lowest point of $0.3400 on 09/22/22. With the stock rallying to its 52-week high on 03/09/22, shares of the company touched a low of $0.30 and a high of $3.35 in 52 weeks. It has reached a new high 4 times so far this year and lost -84.34% or -$1.9198 in price. In spite of this, the price is down -89.85% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
22 days have passed since Akebia Therapeutics Inc. (AKBA) last reported insider trading activity. Burke Steven Keith, who is SVP, Chief Medical Officer, most recently acquired $1,147 shares at $0.36 per share on Aug 31. In this transaction, the insider spent $416. Director, GILMAN STEVEN C, disposed of 4,567 shares at a price of $0.36 on Jun 03. The insider now owns more than $1,653 worth of shares. Prior to that, SVP, Chief Medical Officer Burke Steven Keith went on to Sale 7,656 shares at $2.17 each on Mar 01. An amount of $16,619 was transacted.
Akebia Therapeutics Inc. (AKBA) stock’s beta is 1.46. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.21, the price-to-book (PB) ratio at 1.04.
The quick ratio of Akebia Therapeutics Inc. for the three months ended June 29 was 1.10, and the current ratio was 1.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 1.58 for the quarter ending June 29. Its gross profit as reported stood at $60.18 million compared to revenue of $213.58 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Akebia Therapeutics Inc.’s return on assets was -29.90%.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $29.28 million in the quarter, while revenues of -$62.42 million were grew 383.61%. The analyst consensus anticipated Akebia Therapeutics Inc.’s latest quarter earnings to come in at -$0.31 per share, but it turned out to be $0.15, a 148.40% surprise. For the quarter, EBITDA amounted to $43.33 million. Shareholders own equity worth $183.85 million.
From a technical analysis perspective, let’s take a brief look at Akebia Therapeutics Inc. (AKBA) price momentum. RSI 9-day as of the close on 21 September was 31.81%, suggesting the stock is Neutral, with historical volatility in this time frame at 48.66%.
As of today, AKBA’s price is $0.3620 -8.08% or -$0.0299 from its 5-day moving average. AKBA is currently trading -12.77% lower than its 20-day SMA and -18.06% lower than its 100-day SMA. However, the stock’s current price level is -24.11% below the SMA50 and -86.61% below the SMA200.
The stochastic %K and %D were 5.84% and 12.29%, respectively, and the average true range (ATR) was 0.0258. With the 14-day stochastic at 0.18% and the average true range at 0.0267, the RSI (14) stands at 37.23%. The stock has reached -0.0216 on the 9-day MACD Oscillator while the 14-day reading was at -0.0326.
Piper Sandler downgraded Akebia Therapeutics Inc. (NASDAQ: AKBA) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Akebia Therapeutics Inc. (AKBA) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AKBA, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is AKBA’s price target for the next 12 months?
Analysts predict a range of price targets between $1.25 and $2.00, with a median target of $1.63. Taking a look at these predictions, the average price target given by analysts for Akebia Therapeutics Inc. (AKBA) stock is $1.63.